C. perfringens virulence factors epsilon toxin; alpha toxin; kappa toxin C. perfringens treatment debridement, sometimes amputation, hyperbaric O2 treatment; penicillin and clindamycin Other Gangrene Clostridia C. novyi C. septicum C. sordellii
This chapter discusses the etiology, epidemiology, pathogenesis, clinical signs, prophylaxis, and treatment of diseases produced by C. perfringens Type C. The characteristic microscopic lesion of natural disease in all species is severe necrotizing and hemorrhagic enteritis or colitis with mucosal or ...
A multiplex PCR assay was designed for simultaneous detection and diagnosis of C. perfringens, P. aeruginosa and K. pneumoniae in different clinical samples. A total of 46 clinical samples of patients suspected with the infections were obtained from Sri Venkateswara Institute of Medical Science...
Phospholipases have been detected in a wide range of bacterial genera, sometimes being associated withpathogenicity(virulence). Phospholipases are components of toxins, e.g.,Clostridiumperfringens,the causative organism forgas gangrene, secretesphospholipase Cthat attacks the host phospholipids. ...
(clostridiumperfringens)、破伤风芽孢梭菌(clostridiumtetani)、白喉杆菌(corynebacteriumdiphtheriae)、粪肠球菌(enterococcusfaecalis)、屎肠球菌(enterococcusfaecium)、大肠杆菌、土拉弗朗西斯菌(francisellatularensis)、流感嗜血杆菌(haemophilusinfluenzae)、幽门螺旋杆菌(helicobacterpylori)、嗜肺性军团杆菌(legionellapneumophila)、...
A comparative study of the effects of Escherichia coli and Clostridium perfringens upon boar semen preserved in liquid storage. Anim Reprod Sci. 2017;177:65–78. Parks JE, Lynch DV. Lipid composition and thermotropic phase behavior of boar, bull, stallion, and rooster sperm membranes. Cryobiology...
Bacterial cancer therapy has a long history. In 1813, French physician Arsène-Hippolyte Vautier reported tumour regression in patients with severe infections fromClostridium perfringens[11]. In 1867, German physician Wilhelm Busch observed cancer remission when a patient contracted erysipelas, now known ...
The present invention describes vaccines that comprise C. perfringens Type alpha toxoids, antigenic fragments thereof, inactivated antigenic fragments of C. perfringens </
, Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringens, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, ...
The presence of this domain appears to be necessary for toxicity, but not all enzymes that possess this domain are toxic. Several studies have indicated that membrane active toxins, such as C. perfringens α‐toxin, might be exploited for the treatment of oncogenic disease.Richard W. Titball...